Theranostic drug test incorporating the bone‐marrow microenvironment can predict the clinical response of acute myeloid leukaemia to chemotherapy
Open Access
- 28 April 2020
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 189 (6), E254-E258
- https://doi.org/10.1111/bjh.16684
Abstract
No abstract availableFunding Information
- Science Foundation Ireland (12/TIDA/B2388)
- Irish Cancer Society (BCNI,14/ICS/B3042)
This publication has 14 references indexed in Scilit:
- Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AMLScientific Reports, 2018
- Can we forecast induction failure in acute myeloid leukemia?Haematologica, 2018
- Tracing the origins of relapse in acute myeloid leukaemia to stem cellsNature, 2017
- A 17-gene stemness score for rapid determination of risk in acute leukaemiaNature, 2016
- Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testingDrug Discovery Today, 2016
- Acute Myeloid LeukemiaThe New England Journal of Medicine, 2015
- Bone marrow–on–a–chip replicates hematopoietic niche physiology in vitroNature Methods, 2014
- A novel three-dimensional stromal-based model forin vitrochemotherapy sensitivity testing of leukemia cellsLeukemia & Lymphoma, 2013
- The development of a three-dimensional scaffold for ex vivo biomimicry of human acute myeloid leukaemiaBiomaterials, 2010
- Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal regionNature Biotechnology, 2007